Bumbershoot Holdings L.P. is a private investment partnership launched in Oct-2015.
The partnership uses a fundamental investment strategy as a “quality over quantity” approach to identifying and evaluating great businesses. It primarily invests in small- and mid- capitalization public companies which are headquartered in the U.S. and listed on a domestic exchange. It maintains a relatively concentrated portfolio with approximately 60%-75% of assets in its top-15 holdings. The partnership utilizes low levels of leverage and hedges net long exposure through various short positions and equity derivatives, as dictated by overall market conditions.
Oil midstream professional with a focus on Bakken/NorthDakota midstream assets. Market Analysis, Project Analysis, Competitive Analysis, and Cash Flow Analysis are a few of my favorite things. Some exposure with downstream assets, refined products, and gas.
I have been an Analyst on both the Buyside and Sellside. In addition, I have worked in a Corporate Strategy and Finance role for technology services companies. For many years I've been building quantitative models to create risk-adjusted, return-driven products for DIY individual investors through our platform Graycell Advisors. Our biotech related product - The Prudent Biotech Portfolio - is a quantitative-driven systematic investing product.
For the year 2016, the Prudent Biotech Portfolio was up +7%, compared to IBB (representing Nasdaq Biotech Index) decline of -21%. In addition, the Graycell Smallcap Portfolio was up +71% compared to benchmark Russell 2000 Index gain of +19%.
We invite you to take a look at the Graycell Advisors and Prudent Biotech websites for Performance, Philosophy, and Approach, and decide for yourself if the Biotech and Small Cap products can contribute to your investment objectives.
You can even view Samples, Register for a Free Pick from the Portfolio, and also check the Risk-free Subscription with a 60-day Money-back Guarantee.
Nothing here or on the site constitutes a personalized investment recommendation, and stocks mentioned in the reports/articles/comments may be now or in the past, part of the portfolios recommended by Graycell Advisors and related entities. Graycell Advisors and related entities are not a Registered Investment Advisor (RIA).
Any questions, please write to Support @ PrudentBiotech.com
I am an individual Value investor with a long term view, with a background in engineering. I understand and have an interest in business and operations.
That said, I see the value in quantitative investing and the use of historical data. This allows me to assess the probability of an investment strategy to perform in the future. I avoid speculation, unfounded claims and market timing.
My focus is on long ideas with a contrarian and deep value spin, but I also work elements of momentum into my strategies as well.
Click the “Follow” button above to receive notifications of my new articles!
Dr. George S. Mack is an analyst, managing director and founder at BioDecade where he writes proprietary biotech stock research for clients. He also performs interviews with biotech analysts and biotech CEOs for publications, including The Life Sciences Report.
Mack has authored for Nature Biotechnology, Nature Medicine and the Journal of the National Cancer Institute. He has been a consulting analyst to Decision Resources, and he has been a major contributor to Buyside Magazine, Wall Street Research and Reuters-Multex where he helped develop products intended for institutional investors.
Dr. Mack is a graduate of the University of South Carolina in Columbia and the Medical University of South Carolina in Charleston.
I am a final-year PhD student in Accounting at University of Toronto. My doctoral dissertation is on activist short selling - short sellers publicly talk down stocks to benefit their short positions. The main purpose of this SA column is to apply my academic research findings to real-life investing decisions.
Spent my entire 28 year career on Wall Street with over a decade at Bear Stearns. No "Wall Street Titan" in real life but WST is an alias that I've used for years on Yahoo so I use it when I write on SA. I have gained a significant amount of knowledge regarding the stem cell sector over the years and have recently launched a premium service covering this exciting area.
EP Vantage is a forward-looking comment and analysis service tailored to the needs of pharma and finance professionals, focusing on the events that will define the future of companies, products and therapy areas. Written by experienced journalists, EP Vantage provides timely financial analysis of regulatory and patent decisions, marketing approvals, licensing deals, and M&A, giving fresh angles and insight to both current and future industry triggers. EP Vantage is powered by EvaluatePharma, the industry leader in consensus forecasts.
To follow me click the "Follow" button! (Easy right?)
Kumquat Research is a college student and fund manager who has been investing for 4 years. He writes mostly about the technology sector and about event-driven and momentum opportunities across various industries and sectors. He is currently studying for degrees in both finance and computer science at the University of Maryland. Some of his interests include technology, programming, drumming, video games (developing and playing) and astronomy. Articles written and comments posted by Kumquat Research are NOT financial or investment advice, and only express his opinion. Do your own due diligence!
MD, MBA (Finance, NYU-Stern), certificate in financial modeling (Wharton). *Tipranks profile not accurate as doesn't pick up my premium ratings. Founder: Vasuda Healthcare Analytics (premium U.S. Biotech/pharma research) and Trident Asian Research (premium Asian investments research, www.tridentasia.com)
- Investment insights contributor: SumZero, Buy-side Institutional Platform (sumzero.com). Members of the platform include some of the largest hedge funds and asset managers.
-Former Insight Provider for Smartkarma Intelligent Investing (www.smartkarma.com): Institutional Investments Research Platform (was ranked among top 10 out of over 100 contributors). Clients included some of the largest hedge funds and asset managers.
- Buy-side equity research analyst covering mainly small-cap, emerging pharma/ biotech companies. M.D. with over 18 years of clinical experience (in the U.S. and India), still retaining full medical license in India. M.B.A. with finance and financial markets specialization from New York University Stern School of Business.
- Expert in picking healthcare-related investments, especially biotechnology and pharmaceuticals (focus on small, emerging companies). Investments are selected based on detailed due diligence, including proprietary DCF valuation models. Value investor with long-term horizon.
- Founder, managing principal of Vasuda Capital Management, healthcare-focused investment management firm, vasudacapitalmanagement.com. Registered Investment Advisor in Massachusetts.
- Also started and continue to sponsor Vasuda Global Orphan/ Rare disease biotechnology index, the first global equity index covering rare/orphan disease sector. Index quotes are available on bloomberg/reuters terminals.
I am a Ph.D. level scientist at a major pharmaceutical company. Previously I was an NIH Cancer Postdoctoral fellow at UPENN. Through my extensive research background, I am able to quickly decipher clinical information and act on it. I specialize in analyzing and trading biotech/healthcare stocks both long and short. I maintain a few core positions and trade clinical events based on extensive research to realize large percentage gains. I am open to opportunities in consulting for financial firms or local advisors. Please contact me if you are interested.
NYC-based investment professional. Background in value investing and growth at reasonable price within the context of long/short equity, with additional focus on credit, sovereign debt, commodities, and currencies as part of an overall global macro focus.
I am not always directly active in article comments streams, so if you wish to contact directly, you can PM me on-site or send messages to this address: LSI.firstname.lastname@example.org
I am professional with many years of experience in the pharmaceutical, biotech and device industry covering all functional areas from R&D to product commercialization. I write on Seeking Alpha regarding topics that I find interesting and focus on in depth financial and scientific research.
Data Center Knowledge - Contributor: writing about data centers REITs -- a new and growing asset class -- attempting to bridge the gap between technology & traditional REIT investors.
Researching and writing at the corner of Main St. & Wall St. where real estate often intersects with trends in: technology, ecommerce, office/industrial, healthcare, cloud computing, energy infrastructure & green initiatives.
Recently covered breaking news and actionable ideas REIT ideas for Benzinga "REIT Beat," now Contributor/Sr. REIT Expert. Select articles featured on Investopedia.com, Seeking Alpha, and published on Yahoo! Finance, Google, MSN, Finviz and many other financial portals. Recent Select Freelance contributor for Motley Fool, writing about REITs and real estate topics for the Financial Bureau.
I have over 25 years of experience as a: developer of institutional quality office and industrial facilities, general contractor, homebuilder, managing general partner for private limited partnerships, and have performed consulting and transactional real estate services for others, including entitlements for planned commercial/office/industrial developments.
Past job experience included: V.P. of Energy Services for a Florida based Mechanical Contracting company, which subsequently was acquired by EMCOR (NYSE: EME). Responsibilities included development and "financial engineering" of projects to reduce energy consumption and total cost of ownership solutions, partnered with the two major Florida electric utilities, and private companies, (including Enron Energy Services!).
Education: UCLA - BA Economics, including graduate coursework in Real Estate Finance.
Masters Degree from St. Thomas University - Miami, FL
Prescience Point's founders have over 25 years of combined Wall Street experience, and a significant track-record of successful short recommendations.
The sole focus of our company is to conduct comprehensive fundamental research, and uncover companies that are engaging in fraudulent or misleading business practices. We partner with leading hedge funds, private investigators, accountants, lawyers and industry experts to conduct our research process. We take an activist role to communicate our findings to regulators, shareholders, and other public constituents.
Our firm was founded on the belief that investors deserve full and complete honesty, transparency and accountability from corporations they invest with. We set high expectations and standards for our research process and opinions, and strive to achieve the respect from our readers for our integrity, intellectual honesty, analytical rigor, and accuracy of our conclusions.
A veteran of the pharma industry. Specializing in the analysis of small pharma companies with a focus on the pipeline and opportunities for licensing or major deals with large pharma. Financial analysis including burn rate, venture capital funding, and cash flow.
I seek to liberate investors from the chains of borrowed opinions by teaching metric awareness that leads to the formation of your own opinions. I am a retail investor that gathers, processes and analyzes significantly more data than average. I share that data in my articles. I let the data do the talking. I am only taking dictation as the data tells its message.
I am a part time investor focused on building my family's wealth incrementally over the long term by investing in companies that are well positioned to benefit from important macroeconomic themes. I have a passion for research and hold a M.S from the University of Pennsylvania. I have been an active investor for well over a decade and consider the understanding of global markets and major economic themes as one of my life's passions. I believe that investors can build wealth over the long term by ignoring short term market fluctuations and market "noise" to focus on global economic themes and fundamental company performance.
Retired, late 50's
Hold CFP designation. Passed CFP exam Nov 2000
Author of "IRA: A Quck Reference Guide". Available on Amazon as an e-book.
Author of "Retirement Investing for INCOME ONLY: How to invest for relaible income in Retirement ONLY from Dividends"
I joined Seeking Alpha as a Senior Editor in June 2012, and left to pursue other opportunities in late 2016. I managed the Dividends, Income & Retirement and Expert Insight platforms. D&I focuses on income investment strategies and dividend investment-focused content for investors from the accumulation stage to retirement. The purpose of Expert Insight is to expand and elevate the quality of Seeking Alpha's content by including articles from an industry insider's point of view, designed to help investors make more informed decisions as they consider specific sectors and trends within those sectors for their investing strategies, e.g., utilities or technology. Expert Insight articles offer more of a macro, 30,000-foot-view that goes beyond investment analysis or stock recommendations. I also curated the Dividends & Income Digest, a bi-weekly publication that takes a look at a question that is compelling and relevant to the community, showcases the responses of DI thought leaders, and serves as a round-up of top DI articles. I have a particular interest in retirement-related content, particularly with regard to using a dividend strategy to create a steady income stream for those golden years.
Zach is a biotech investor with PhD training in Biochemistry and Molecular Biology. In real life, he is a scientific writer specializing in continuing medical education. He hopes to provide a crucial piece of total due diligence as well as interesting insight into clinical findings that may impact readers' portfolios and lives.
Ever feel like trading is like rolling dice? In a way, it is, because every mathematical model of the market includes a stochastic aspect. But I believe we can load the dice in our favor through the use of statistics. Understanding both the stock market and each individual stock as a sort of random process with its own characteristics allows us to more accurately predict what it will do in the future. Coupling statistics with fundamental analysis, I have the goal of revealing to you the hidden patterns within stocks so that you may do what you wish with that information.
Former broker, now an independent analyst/writer on Seeking Alpha and founder and editor of the Growth Stock Forum. Focusing on small-cap, mid-cap and biotech stocks. Looking for substantial sales and earnings growth potential and seeking the best risk-adjusted returns from my stock selection. Taking advantage of medium to long-term momentum.
My articles represent my personal opinion and analysis and should not be regarded as investment advice in any way. Readers and subscribers should do their own due diligence and/or consult their financial advisor before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.
Exclusive research: http://seekingalpha.com/author/oneil-trader/research
Principal En-lightener - Purveyor of Darkness.
And Now - The Gift...
Stupid is as stupid does - Forrest Gump;
You can't fix stupid, no pill for it, it's fo'ever - Ron White ;
There are idiots, look around - Larry Summers ;
To avoid the pernicious global plague of stupidity, drink the Kool-Aid and become one of the innoculati. The Kool-Aid is available at [VIRUS REMOVED BY ECHELON UNDER ORDER OF PATRIOT ACT II ... transmission terminated]